Marvisi Chiara, Muratore Francesco, Cusenza Vincenza Ylenia, Nicoli Davide, Farnetti Enrico, Bonanno Orsola, Spaggiari Lucia, Banzi Maria, Longo Caterina, Salvarani Carlo
Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Università di Modena e Reggio Emilia, Modena, Italy.
J Immunother Cancer. 2025 Jul 31;13(7):e012410. doi: 10.1136/jitc-2025-012410.
The use of immune checkpoint inhibitors in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is unknown. Concerns are particularly about their safety, due to their potential capacity to exacerbate inflammatory symptoms. Further, there is a lack of data about their role in controlling the UBA1 clones. In this clinical case, we report a successful use of cemiplimab in a patient with VEXAS syndrome and a concomitant diagnosis of metastatic squamous cell carcinoma.
免疫检查点抑制剂在VEXAS（空泡、E1酶、X连锁、自身炎症性、体细胞）综合征中的应用尚不清楚。由于其可能加剧炎症症状，人们尤其担心其安全性。此外，关于它们在控制UBA1克隆中的作用缺乏数据。在本临床病例中，我们报告了西妥昔单抗在一名患有VEXAS综合征并伴有转移性鳞状细胞癌诊断的患者中的成功应用。
